Although the whole mechanism should be additionally studied to give a thorough understanding of the activating cascade and all the partners involved in it, our studies set the basis for re-evaluating EGFR inhibition in meningioma as a possible therapeutic option. The gene discussed is EGFR; the disease is meningioma.